Lineage Cell Therapeutics, Inc. (LCTX) Social Stream



Lineage Cell Therapeutics, Inc. (LCTX): $0.90

0.02 (-2.53%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

D

Add LCTX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#235 of 337

in industry

LINEAGE CELL THERAPEUTICS INC (LCTX) Price Targets From Analysts

The tables below show the price targets and recommendations analysts covering LCTX.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-12-02 5 $8 $5 $6.4 $1.22 424.59%
2021-12-22 6 $8 $5 $6.4 $1.22 424.59%
2022-06-03 5 $8 $6 $6.75 $1.22 453.28%
2022-06-14 6 $8 $4 $6.2 $1.22 408.2%
2022-08-16 7 $8 $4 $6 $1.22 391.8%
2022-10-04 7 $9 $4 $6.166 $1.22 405.41%
2023-05-12 8 $9 $4 $6 $1.22 391.8%
2023-08-11 7 $9 $4 $6 $1.22 391.8%
2023-10-19 6 $7 $4 $5.5 $1.22 350.82%
2023-11-10 6 $7 $4 $5.5 $1.22 350.82%
2023-11-20 6 $7 $2 $4.833 $1.22 296.15%

The Trend in the Analyst Price Target


LCTX's average price target has moved down $1.17 over the prior 27 weeks.

Over the past 38 weeks, LCTX's average upside potential has been 347.77%.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2023-03-13 8 9 4 6.0 1.42 322.54%
2023-04-26 8 9 4 6.0 1.35 344.44%
2023-05-12 8 9 4 6.0 1.38 334.78%
2023-10-20 7 7 4 5.5 1.20 358.33%
2023-11-10 6 7 4 5.5 1.04 428.85%

LCTX Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1 6 0 0 0 0 6

The Trend in the Broker Recommendations


Over the past 52 weeks, LCTX's average broker recommendation rating improved by 0.25.

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for LCTX as an investment opportunity.

  • LINEAGE CELL THERAPEUTICS INC's average analyst price target is higher than 58.94% of all US stocks.
  • To contextualize these metrics, consider that out of all US stocks, LINEAGE CELL THERAPEUTICS INC's upside potential (average analyst target price relative to current price) is higher than 1019.71% of them.
  • LCTX has a greater number of analysts covering the stock than 810.81% of stocks in the small market cap category.
  • In the context of stocks in the small market cap category, LINEAGE CELL THERAPEUTICS INC's variance in analysts' estimates is lower than -631.53% of them.

In the Pharmaceutical Products industry, CVM, CRBU, and FUSN are the three stocks most similar to LINEAGE CELL THERAPEUTICS INC regarding the price target and analyst recommendation information presented here.

Is LCTX a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!